The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy.
 
Amishi Yogesh Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst)
 
Jianjun Gao
Consulting or Advisory Role - AstraZeneca; crispr therapeutics; Infinity Pharmaceuticals; Janssen; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Genentech; Gilead Sciences; Immunomedics; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Exelixis; Genentech/Roche; Gilead Sciences; Gilead Sciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Macrogenics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck (Inst)
 
Rohit K. Jain
Honoraria - Alphasights (I)
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Pfizer; Seattle Genetics/Astellas; Taiho Oncology (I)
Speakers' Bureau - Gilead Sciences; Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb
 
Alex Stevenson
Employment - 4D Pharma
Leadership - 4D Pharma; 4D Pharma; 4D Pharma; C4X Discovery
Stock and Other Ownership Interests - 4D Pharma; 4D Pharma; 4D Pharma; C4X Discovery; Microbiomics Limited; The Microbiota Company Limited
 
Gayle Fyvie
Employment - 4D Pharma
 
Nina Jane Gaw
Employment - 4D Pharma
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - Ipsen; Xencor; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); ArQule (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Onco Response (Inst); Purple Biotech (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)